<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of visceral leishmaniasis in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of visceral leishmaniasis in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment of visceral leishmaniasis in adults</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1"> </td> <td class="subtitle1">Preferred therapy and duration</td> <td class="subtitle1">Alternative therapy</td> <td class="subtitle1">Other options/issues</td> </tr> <tr> <td class="divider_bottom" rowspan="3"><strong>VL in previously immunocompetent patient</strong></td> <td class="border_bottom_white"><strong>East Africa:</strong> Sodium stibogluconate* 20 mg/kg IV or IM daily <strong>PLUS</strong> paromomycin 15 mg/kg IM daily for <span class="nowrap_whitespace">17 days<sup>¶</sup><sup>[1,2]</sup></span></td> <td class="border_bottom_white"><strong>East Africa:</strong> Liposomal amphotericin B 3 mg/kg IV daily alone for <span class="nowrap_whitespace">10 days<sup>[3,4]</sup></span> or <span class="nowrap_whitespace">miltefosine<sup>◊</sup></span> <strong>PLUS</strong> paromomycin 20 mg/kg IM daily for <span class="nowrap_whitespace">14 days<sup>¶[5]</sup></span></td> <td class="divider_bottom" rowspan="3"> <p>Nutritional support, treatment of hemorrhagic or infectious complications.</p> Sodium stibogluconate* 20 mg/kg IV or IM daily for 28 days or amphotericin B lipid complex injection or amphotericin B deoxycholate (optimal regimen not established). </td> </tr> <tr> <td class="border_bottom_white"><strong>South Asia:</strong> Liposomal amphotericin B 3 mg/kg IV on days 1 to 5, 14, and <span class="nowrap_whitespace">21<sup>Δ</sup></span></td> <td class="border_bottom_white"><strong>South Asia:</strong> Miltefosine<sup>◊</sup> for 28 days</td> </tr> <tr class="divider_bottom"> <td><strong>Europe/Americas:</strong> Liposomal amphotericin B 3 mg/kg IV daily for <span class="nowrap_whitespace">7 days<sup>[6]</sup></span></td> <td><strong>Europe/Americas:</strong> Amphotericin B lipid complex injection or amphotericin B deoxycholate (optimal regimen not established)</td> </tr> <tr> <td class="divider_bottom" rowspan="7"><strong>HIV-VL coinfection</strong></td> <td class="border_bottom_white"><strong>East Africa:</strong> Liposomal amphotericin B 5 mg/kg IV on days 1, 3, 5, 7, 9, and 11 <strong>PLUS</strong> <span class="nowrap_whitespace">miltefosine<sup>◊</sup></span> for <span class="nowrap_whitespace">28 days<sup>[7]</sup></span></td> <td class="border_bottom_white"><strong>East Africa:</strong> Liposomal amphotericin B 5 mg/kg IV on days 1 to 5, 10, 17, and <span class="nowrap_whitespace">24<sup>[7]</sup></span></td> <td rowspan="3"> <p>ART should be initiated or optimized.</p> Alternative regimens for treatment failure in East Africa and South Asia: Sodium stibogluconate* 20 mg/kg IV or IM daily for 28 days or amphotericin B lipid complex injection (optimal regimen not established). </td> </tr> <tr> <td class="border_bottom_white"><strong>South Asia:</strong> Liposomal amphotericin B 5 mg/kg IV on days 1, 3, 5, 7, 9, and 11 <strong>PLUS</strong> <span class="nowrap_whitespace">miltefosine<sup>◊</sup></span> for <span class="nowrap_whitespace">14 days<sup>[7]</sup></span></td> <td class="border_bottom_white"><strong>South Asia:</strong> Liposomal amphotericin B 5 mg/kg IV on days 1 to 4, 8, 10, 17, and <span class="nowrap_whitespace">24<sup>[7]</sup></span></td> </tr> <tr> <td><strong>Europe/Americas:</strong> Liposomal amphotericin B 3 mg/kg/day up to a total dose of <span class="nowrap_whitespace">40 mg/kg<sup>[6]</sup></span></td> <td><strong>Europe/Americas:</strong> Amphotericin B deoxycholate 0.7 mg/kg<strong>/day</strong> for 28 days, maximum dose 50 mg/day</td> </tr> <tr class="border_bottom_white"> <td>Secondary prophylaxis<sup>§</sup>:</td> <td> </td> <td> </td> </tr> <tr> <td class="border_bottom_white"> <ul class="decimal_heading"> <li><strong>East Africa:</strong> Pentamidine isethionate 4 mg/kg (300 mg for adults) IV every 3 to <span class="nowrap_whitespace">4 weeks<sup>[7,8]</sup></span></li> </ul> </td> <td class="border_bottom_white"><strong>East Africa:</strong> Sodium stibogluconate* 20 mg/kg IV or IM every 4 weeks</td> <td class="divider_bottom" rowspan="3"> </td> </tr> <tr class="border_bottom_white"> <td> <ul class="decimal_heading"> <li><strong>South Asia:</strong> Liposomal amphotericin B 3 to 5 mg/kg IV every 3 to <span class="nowrap_whitespace">4 weeks<sup>[7]</sup></span></li> </ul> </td> <td><strong>South Asia:</strong> Amphotericin B deoxycholate 1 mg/kg IV every 3 to <span class="nowrap_whitespace">4 weeks<sup>[7]</sup></span></td> </tr> <tr class="divider_bottom"> <td> <ul class="decimal_heading"> <li><strong>Europe/Americas:</strong> Liposomal amphotericin B 3 to 5 mg/kg IV every 3 to <span class="nowrap_whitespace">4 weeks<sup>[6]</sup></span></li> </ul> </td> <td><strong>Europe/Americas:</strong> Amphotericin B deoxycholate 1 mg/kg IV every 3 to <span class="nowrap_whitespace">4 weeks<sup>[6]</sup></span></td> </tr> <tr> <td rowspan="3"><strong>Post kala-azar dermal leishmaniasis (PKDL)</strong></td> <td class="border_bottom_white"><strong>East Africa:</strong> Sodium stibogluconate* 20 mg/kg IV or IM daily for 30 to <span class="nowrap_whitespace">60 days<sup>¥</sup></span></td> <td rowspan="3">Liposomal amphotericin B (optimal regimen not established but most reports achieved total dose of ≥30 mg/kg)</td> <td rowspan="3"> </td> </tr> <tr class="border_bottom_white"> <td><strong>South Asia:</strong> Miltefosine<sup>◊</sup> 2.5 mg/kg/day orally for 12 weeks (maximum dose <span class="nowrap_whitespace">150 mg/day)<sup>‡</sup></span></td> </tr> <tr> <td><strong>Europe/Americas:</strong> Miltefosine<sup>◊</sup> 2.5 mg/kg/day orally for 12 weeks (maximum dose <span class="nowrap_whitespace">150 mg/day)<sup>‡</sup></span></td> </tr> </tbody></table></div><div class="graphic_lgnd">Dosing in this table is for adult patients with normal organ (eg, kidney) function. For additional detail, refer to Lexicomp drug monographs.</div><div class="graphic_footnotes"><p>VL: visceral leishmaniasis; IV: intravenous; IM: intramuscular; ART: antiretroviral therapy.</p>
<p>* Not available in the United States or Canada. Consult local health agencies for availability.</p>
<p>¶ Parenteral paromomycin is not available in the United States.</p>
<p>Δ Shorter regimens that achieve 10 to 20 mg/kg total dose (for example, 10 mg/kg single dose, 10 mg/kg/day for 2 days, or 4 mg/kg/day for 5 days) also have high efficacy with low rates of adverse <font class="nowrap_whitespace">effects<sup>[9]</sup>.</font></p>
<p>◊ Do not use in patients who are pregnant or breastfeeding. Miltefosine is available in 50 mg capsules. United States product labeling recommends 50 mg twice daily for patients weighing 30 to 44 kg and 50 mg 3 times daily for patients weighing ≥45 kg (maximum dose: 150 mg/day). Other sources may provide different dosing <font class="nowrap_whitespace">recommendations<sup>[7,10]</sup>.</font></p>
<p>§ Secondary prophylaxis should be administered to all patients with HIV-VL coinfection. Continue until CD4 count is &gt;350 cells/microL (or the HIV viral load is undetectable) for at least 6 months and there is no evidence of VL <font class="nowrap_whitespace">relapse<sup>[7]</sup>.</font></p>
<p>¥ Conventional treatment for East African PKDL consists of sodium stibogluconate 20 mg/kg/day for 30 to 60 days, but data suggest sodium stibogluconate (30 mg/kg/day for a minimum of 17 days) plus paromomycin (15 mg sulphate/kg/day for 17 days) may have higher <font class="nowrap_whitespace">efficacy.<sup>[11]</sup></font></p>
‡ Stated regimen is first-line treatment for PKDL; however, increasing failure rates have been <font class="nowrap_whitespace">reported.<sup>[12,13]</sup></font></div><div class="graphic_reference">References:
<ol>
<li>Musa A, Khalil E, Hailu A, et al. Sodium stibogluconate (SSG) &amp; paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: A randomised controlled trial. PLoS Negl Trop Dis 2012; 6:e1674.</li>
<li>Sundar S, Singh A. Recent developments and future prospects in the treatment of visceral leishmaniasis. Ther Adv Infect Dis 2016; 3:98.</li>
<li>Salih NA, van Griensven J, Chappuis F, et al. Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: How effective is treatment for this neglected disease? Trop Med Int Health 2014; 19:146.</li>
<li>Mueller YK, Kolaczinski JH, Koech T, et al. Clinical epidemiology, diagnosis and treatment of visceral leishmaniasis in the Pokot endemic area of Uganda and Kenya. Am J Med Hyg 2014; 90:33.</li>
<li>Musa AM, Mbui J, Mohammed R, et al. Paromomycin and miltefosine combination as an alternative to treat patients with visceral leishmaniasis in eastern Africa: a randomized, controlled, multicountry trial. Clin Infect Dis 2022.</li>
<li>Guideline for the treatment of leishmaniasis in the Americas. Pan American Health Organization. June 2022. Available at: <a href="https://www.paho.org/en/documents/guideline-treatment-leishmaniasis-americas-second-edition" target="_blank">https://www.paho.org/en/documents/guideline-treatment-leishmaniasis-americas-second-edition</a> (Accessed on June 30, 2022).</li>
<li>WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia. World Health Organization, Geneva 2022. Available at: <a href="https://www.who.int/publications/i/item/9789240048294" target="_blank">https://www.who.int/publications/i/item/9789240048294</a> (Accessed on June 14, 2022).</li>
<li>Diro E, Ritmeijer K, Boelaert M, et al. Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients, the first twelve months of a prospective cohort study. PLoS Negl Trop Dis 2015; 9:e0004087.</li>
<li>Control of the leishmaniases. WHO Technical Report Series. World Health Organization, Geneva, 2010. Available at: <a href="https://apps.who.int/iris/bitstream/handle/10665/44412/WHO_TRS_949_eng.pdf" target="_blank">https://apps.who.int/iris/bitstream/handle/10665/44412/WHO_TRS_949_eng.pdf</a> (Accessed on July 15, 2022).</li>
<li>Miltefosine. US Food and Drug Administration (FDA) approved product information. Revised May 2021. US National Library of Medicine. (Available online at <a href="www.dailymed.nlm.nih.gov" target="_blank">www.dailymed.nlm.nih.gov</a>).</li>
<li>Abongomera C, Gatluak F, Buyze J, Ritmeijer K. A comparison of the effectiveness of sodium stibogluconate monotherapy to sodium stibogluconate and paromomycin combination for the treatment of severe post kala azar dermal leishmaniasis in South Sudan - A retrospective cohort study. PloS One 2016; 11:e0163047.</li>
<li>Ramesh V, Singh R, Avishek K, et al. Decline in clinical efficacy of oral miltefosine in treatment of post kala-azar dermal leishmaniasis (PKDL) in India. PLoS Negl Trop Dis 2015; 9:e0004093.</li>
<li>Ghosh S, Das NK, Mukherjee S, et al. Inadequacy of 12-Week miltefosine treatment for Indian post-kala-azar dermal leishmaniasis. Am J Trop Med Hyg 2015; 93:767.</li>
</ol></div><div id="graphicVersion">Graphic 80899 Version 10.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
